1921
Volume 101, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

São Tomé and Príncipe (STP) uses a selective hepatitis B birth-dose vaccination (HepB-BD) strategy targeting infants born to mothers who test positive for hepatitis B virus (HBV) surface antigen. We conducted a field assessment and economic analysis of the HepB-BD strategy to provide evidence to guide development of cost-effective policies to prevent perinatal HBV transmission in STP. We interviewed national stakeholders and key informants to understand policies, knowledge, and practices related to HepB-BD, vaccine management, and data recording/reporting. Cost-effectiveness of the existing strategy was compared with an alternate approach of universal HepB-BD to all newborns using a decision analytic model. Incremental cost-effectiveness ratios (ICERs) were calculated in 2015 USD per HBV-associated death and per chronic HBV case prevented, from the STP health-care system perspective. We found that STP lacked national or facility-specific written policies and procedures related to HepB-BD. Timely HepB-BD to eligible newborns was considered a high priority, although timeliness of HepB-BD was not monitored. Compared with the existing selective vaccination strategy, universal HepB-BD would result in a 19% decrease in chronic HBV infections per year at overall cost savings of approximately 44% (savings of USD 5,441 each year). We estimate an ICER of USD 5,012 saved per HBV-associated death averted. The existing selective HepB-BD strategy in STP could be improved through documentation of policies, procedures, and timeliness of HepB-BD. Expansion to universal newborn HepB-BD without maternal screening is feasible and could result in cost savings if actual implementation costs and effectiveness fall within the ranges modeled.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0926
2019-08-05
2020-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/4/tpmd180926.html?itemId=/content/journals/10.4269/ajtmh.18-0926&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2001. Introduction of Hepatitis B Vaccine into Childhood Immunization Services. Geneva, Switzerland: WHO.
    [Google Scholar]
  2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP, 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529538.
    [Google Scholar]
  3. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS, 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34: 13291339.
    [Google Scholar]
  4. Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A, 2013. Hepatitis B Vaccines. Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Vaccines. Philadelphia, PA: Elsevier, 205234.
    [Google Scholar]
  5. World Health Organization, 2017. Hepatitis B vaccines: WHO position paper–July 2017. Wkly Epidemiol Rec 92: 369392.
    [Google Scholar]
  6. Gavi, Sao Tome and Principe country fact sheet. Available at: http://www.gavi.org/country/sao-tome-and-principe/. Accessed July 3, 2016.
  7. Instituto Nacional de Estatística de São Tomé e Príncipe (INE), Ministério da Saúde de São Tomé e Príncipe, Macro Health, 2010. Inquérito Demográfico e Sanitário, São Tomé e Príncipe (IDS STP) 2008–2009. Calverton, MD: INE.
    [Google Scholar]
  8. World Health Organization, UNICEF. WHO-UNICEF Estimate of HepB-BD Coverage. Available at: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragehepb_bd.html. Accessed January 1, 2016.
    [Google Scholar]
  9. Programa das Nações Unidas para o Desenvolvimento - PNUD/São Tomé e Príncipe, and ICF Macro, 2015. Resultados dos Biomarcadores do Inquérito de Indicadores Múltiplos (MICS) São Tomé e Príncipe 2014. São Tomé, São Tomé e Príncipe: PNUD/São Tomé e Príncipe and ICF Macro.
    [Google Scholar]
  10. Team RC, 2014. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
    [Google Scholar]
  11. Lien TX, Tien NT, Chanpong GF, Cuc CT, Yen VT, Soderquist R, Laras K, Corwin A, 2000. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 62: 301309.
    [Google Scholar]
  12. Lawn JE et al., 2016. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet 387: 587603.
    [Google Scholar]
  13. Ekra D, Herbinger KH, Konate S, Leblond A, Fretz C, Cilote V, Douai C, Da Silva A, Gessner BD, Chauvin P, 2008. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d’Ivoire. Vaccine 26: 27532761.
    [Google Scholar]
  14. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pai NP, 2012. Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy (1980–2010). Am J Gastroenterol 107: 13061313.
    [Google Scholar]
  15. Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ, 1996. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117: 313325.
    [Google Scholar]
  16. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA, 1995. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 274: 12011208.
    [Google Scholar]
  17. Beasley RP, Hwang LY, Lin CC, Chien CS, 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 2: 11291133.
    [Google Scholar]
  18. Harvard T.H. Chan School of Public Health–Center for Health Decision Sciences, 2015. 3. Original EPIC-1 Data Source: Harvard Dataverse. Cambridge, MA: Chan School of Public Health–Center for Health Decision Sciences.
    [Google Scholar]
  19. Schackman BR, Neukermans CP, Fontain SN, Nolte C, Joseph P, Pape JW, Fitzgerald DW, 2007. Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti. PLoS Med 4: e183.
    [Google Scholar]
  20. Kuznik A, Lamorde M, Nyabigambo A, Manabe YC, 2013. Antenatal syphilis screening using point-of-care testing in sub-Saharan African countries: a cost-effectiveness analysis. PLoS Med 10: e1001545.
    [Google Scholar]
  21. Ott JJ, Stevens GA, Wiersma ST, 2012. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 12: 131.
    [Google Scholar]
  22. Beasley RP, Trepo C, Stevens CE, Szmuness W, 1977. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105: 9498.
    [Google Scholar]
  23. de Franchis R et al., EASL Jury, 2003. EASL international consensus conference on hepatitis B. 13–14 september, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 39 (Suppl 1): S3S25.
    [Google Scholar]
  24. Griffiths UK, Hutton G, Das Dores Pascoal E, 2005. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan 20: 5059.
    [Google Scholar]
  25. Klingler C, Thoumi AI, Mrithinjayam VS, 2012. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine 31: 252259.
    [Google Scholar]
  26. UNICEF, 2018. UNICEF Vaccine Price Data. Available at: http://www.unicef.org/supply/index_57476.html. Accessed November 14, 2018.
    [Google Scholar]
  27. Griffiths UK, Korczak VS, Ayalew D, Yigzaw A, 2009. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 27: 14261432.
    [Google Scholar]
  28. Malcolm D, Roseboom J, Clark C, 1959. Application of a technique for research and development program evaluation. Operations Res 7: 646669.
    [Google Scholar]
  29. World Health Organization, 1996. Hepatitis B and Breastfeeding. Geneva, Switzerland: WHO.
    [Google Scholar]
  30. Shillcutt SD, Walker DG, Goodman CA, Mills AJ, 2019. Cost effectiveness in low-and middle-income countries a review of the debates surrounding decision rules. Pharmacoeconomics 27: 903917.
    [Google Scholar]
  31. World Bank. Open Data Catalogue. Available at: http://data.worldbank.org/. Accessed January 1, 2016.
    [Google Scholar]
  32. World Bank, 2014. GDP Per Capita, PPP (Current International $) International Comparison Database. Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?locations=BJCIST. Accessed June 1, 2016.
    [Google Scholar]
  33. Borresen ML, Koch A, Biggar RJ, Ladefoged K, Melbye M, Wohlfahrt J, Krause TG, 2012. Effectiveness of the targeted hepatitis B vaccination program in Greenland. Am J Public Health 102: 277284.
    [Google Scholar]
  34. Edmond KM, Zandoh C, Quigley MA, Amenga-Etego S, Owusu-Agyei S, Kirkwood BR, 2006. Delayed breastfeeding initiation increases risk of neonatal mortality. Pediatrics 117: e380e386.
    [Google Scholar]
  35. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP, 2018. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 67: 131.
    [Google Scholar]
  36. Chen SC, Toy M, Yeh JM, Wang JD, Resch S, 2013. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics 131: e1135e1143.
    [Google Scholar]
  37. World Health Organization, 2018. Implementation of hepatitis B birth dose vaccination–worldwide, 2016. Wkly Epidemiol Rec 93: 6172.
    [Google Scholar]
  38. World Health Organization, 2017. Global Health Sector Strategy on Viral Hepatitis 2016–2021. Geneva, Switzerland: WHO.
    [Google Scholar]
  39. Gavi, 2019. Gavi Board Starts Framing Alliance’s Approach to 2021–2025 Period. Geneva, Switzerland: Gavi.
    [Google Scholar]
  40. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB, 2016. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis 16: 13991408.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0926
Loading
/content/journals/10.4269/ajtmh.18-0926
Loading

Data & Media loading...

Supplemental Materials

  • Received : 19 Nov 2018
  • Accepted : 20 Jun 2019
  • Published online : 05 Aug 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error